Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4929097 with FOLFOX and Bevacizumab in Metastatic Colorectal Cancer
NCT01270438Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RO4929097 in metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Planned start Dec 2010; status: withdrawn.
02
Drugs
RO4929097
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01270438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01270438.